Newly developed anti‐S100A8/A9 monoclonal antibody efficiently prevents lung tropic cancer metastasis

Kinoshita, Rie; Sato, Hiroki; Yamauchi, Akira; Takahashi, Yuta; Inoue, Yusuke; Sumardika, I Wayan; Chen, Youyi; Tomonobu, Nahoko; Araki, Kota; Shien, Kazuhiko; Tomida, Shuta; Torigoe, Hidejiro; Namba, Kei; Kurihara, Eisuke; Ogoshi, Yusuke; Murata, Hitoshi; Futami, Junichiro; Putranto, Endy Widya; Ruma, I Made Winarsa; Yamamoto, Hiromasa; Soh, Junichi; Hibino, Toshihiko; Nishibori, Masahiro; Kondo, Eisaku; Toyooka, Shinichi; Sakaguchi, Masakiyo

doi:10.1002/ijc.31982

Cited by 36 publications

(26 citation statements)

References 25 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Binds extracellular S100A8/S100A9 heterodimer and therefore reduces metastasis Pre-clinical [236] 2H8 S100P Binds S100P and therefore reduces tumour growth and metastasis Pre-clinical [237] miRNA miR-187-3p S100A4 S100A4 silencing results in reduced metastasis and EMT in HCC Pre-clinical [238] miR-149-3p S100A4…”

Section: Inhibitor S100 Target Mechanism Of Action Current Status Refmentioning

confidence: 99%

“…In terms of neutralising the DAMP molecules S100A8 and S100A9, monoclonal Ab45 was identified to be the most selective among ten anti-S100A8/S100A9 antibodies. In vitro, Ab45 could inhibit S100A8/S100A9-stimulated chemotaxis, and in vitro significantly reduced lung metastasis within a melanoma model [236]. The anti-S100P antibody 2H8 was introduced to inhibit S100P-induced proliferation of pancreatic cancer cells and blocked increased survival induced by S100P after gemcitabine treatment.…”

Section: Neutralising Antibodiesmentioning

confidence: 99%

See 1 more Smart Citation

Friend or Foe: S100 Proteins in Cancer

Allgöwer

Kretz

Karstedt

et al. 2020

Cancers

View full text Add to dashboard Cite

S100 proteins are widely expressed small molecular EF-hand calcium-binding proteins of vertebrates, which are involved in numerous cellular processes, such as Ca2+ homeostasis, proliferation, apoptosis, differentiation, and inflammation. Although the complex network of S100 signalling is by far not fully deciphered, several S100 family members could be linked to a variety of diseases, such as inflammatory disorders, neurological diseases, and also cancer. The research of the past decades revealed that S100 proteins play a crucial role in the development and progression of many cancer types, such as breast cancer, lung cancer, and melanoma. Hence, S100 family members have also been shown to be promising diagnostic markers and possible novel targets for therapy. However, the current knowledge of S100 proteins is limited and more attention to this unique group of proteins is needed. Therefore, this review article summarises S100 proteins and their relation in different cancer types, while also providing an overview of novel therapeutic strategies for targeting S100 proteins for cancer treatment.

show abstract

Section: Inhibitor S100 Target Mechanism Of Action Current Status Refmentioning

confidence: 99%

Section: Neutralising Antibodiesmentioning

confidence: 99%

Friend or Foe: S100 Proteins in Cancer

Allgöwer

Kretz

Karstedt

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…For instance, melanoma cells from distant organs induce S100A8/A9 expression in the lung. Conversely, melanoma cells possessing several receptors that sense the S100A8/A9 ligand are attracted to an enriched S100A8/A9 lung environment [163]. Similarly, S100A8/A9 attracts cancer cells in the lung in prostate cancer murine models [164].…”

Section: Clp and Metastatic Cancers In The Lungmentioning

confidence: 99%

Calprotectin in Lung Diseases

Kotsiou

Papagiannis

Papadopoulou

et al. 2021

IJMS

View full text Add to dashboard Cite

Calprotectin (CLP) is a heterodimer formed by two S-100 calcium-binding cytosolic proteins, S100A8 and S100A9. It is a multifunctional protein expressed mainly by neutrophils and released extracellularly by activated or damaged cells mediating a broad range of physiological and pathological responses. It has been more than 20 years since the implication of S100A8/A9 in the inflammatory process was shown; however, the evaluation of its role in the pathogenesis of respiratory diseases or its usefulness as a biomarker for the appropriate diagnosis and prognosis of lung diseases have only gained attention in recent years. This review aimed to provide current knowledge regarding the potential role of CLP in the pathophysiology of lung diseases and describe how this knowledge is, up until now, translated into daily clinical practice. CLP is involved in numerous cellular processes in lung health and disease. In addition to its anti-microbial functions, CLP also serves as a molecule with pro- and anti-tumor properties related to cell survival and growth, angiogenesis, DNA damage response, and the remodeling of the extracellular matrix. The findings of this review potentially introduce CLP in daily clinical practice within the spectrum of respiratory diseases.

show abstract

“…Kinoshita et al developed a neutralizing anti-S100A8/A9 antibody for blocking ''seed and soil'' cross-talk and found that it efficiently suppressed organ tropic metastasis. 119 Given that numerous DAMPs are released after surgery, the feasibility for the application of neutralizing antibodies is limited. Therefore, therapies targeting the downstream inflammatory signals are better options in the perioperative period.…”

Section: Anti-damps and Related Pyroptosis/ Inflammatory Signalingmentioning

confidence: 99%

Targeting Myeloid-Derived Suppressor Cells for Premetastatic Niche Disruption After Tumor Resection

et al. 2020

View full text Add to dashboard Cite

Surgical resection is a common therapeutic option for primary solid tumors. However, high cancer recurrence and metastatic rates after resection are the main cause of cancer related mortalities. This implies the existence of a “fertile soil” following surgery that facilitates colonization by circulating cancer cells. Myeloid-derived suppressor cells (MDSCs) are essential for premetastatic niche formation, and may persist in distant organs for up to 2 weeks after surgery. These postsurgical persistent lung MDSCs exhibit stronger immunosuppression compared with presurgical MDSCs, suggesting that surgery enhances MDSC function. Surgical stress and trauma trigger the secretion of systemic inflammatory cytokines, which enhance MDSC mobilization and proliferation. Additionally, damage associated molecular patterns (DAMPs) directly activate MDSCs through pattern recognition receptor-mediated signals. Surgery also increases vascular permeability, induces an increase in lysyl oxidase and extracellular matrix remodeling in lungs, that enhances MDSC mobilization. Postsurgical therapies that inhibit the induction of premetastatic niches by MDSCs promote the long-term survival of patients. Cyclooxygenase-2 inhibitors and β-blockade, or their combination, may minimize the impact of surgical stress on MDSCs. Anti-DAMPs and associated inflammatory signaling inhibitors also are potential therapies. Existing therapies under tumor-bearing conditions, such as MDSCs depletion with low-dose chemotherapy or tyrosine kinase inhibitors, MDSCs differentiation using all-trans retinoic acid, and STAT3 inhibition merit clinical evaluation during the perioperative period. In addition, combining low-dose epigenetic drugs with chemokine receptors, reversing immunosuppression through the Enhanced Recovery After Surgery protocol, repairing vascular leakage, or inhibiting extracellular matrix remodeling also may enhance the long-term survival of curative resection patients.

show abstract

Newly developed anti‐S100A8/A9 monoclonal antibody efficiently prevents lung tropic cancer metastasis

Cited by 36 publications

References 25 publications

Friend or Foe: S100 Proteins in Cancer

Friend or Foe: S100 Proteins in Cancer

Calprotectin in Lung Diseases

Targeting Myeloid-Derived Suppressor Cells for Premetastatic Niche Disruption After Tumor Resection

Contact Info

Product

Resources

About